Covered recipient · General Payments record
LILLIAN LEIGH B DAVIS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,317.43
- Reported across 75 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $546.57 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $227.16 | 17 |
| Acerta Pharma LLC | $76.64 | 3 |
| Novo Nordisk AS | $71.90 | 4 |
| Astellas Pharma US Inc | $34.01 | 2 |
| Lilly USA, LLC | $33.08 | 2 |
| Insulet Corporation | $20.71 | 1 |
| ABIOMED | $19.99 | 1 |
| Exact Sciences Corporation | $18.36 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $16.99 | 1 |
| Paratek Pharmaceuticals, Inc. | $14.12 | 1 |
| Amgen Inc. | $13.61 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $5.40 | 01/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994240 | CMS |
| ABBVIE INC. | $15.92 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994242 | CMS |
| ABBVIE INC. | $17.95 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994244 | CMS |
| ABBVIE INC. | $6.94 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994246 | CMS |
| ABBVIE INC. | $16.05 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994248 | CMS |
| ABBVIE INC. | $4.17 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994250 | CMS |
| ABBVIE INC. | $14.93 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994252 | CMS |
| ABBVIE INC. | $8.60 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994254 | CMS |
| ABBVIE INC. | $17.14 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994256 | CMS |
| ABBVIE INC. | $1.97 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994258 | CMS |
| ABBVIE INC. | $21.73 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994260 | CMS |
| ABBVIE INC. | $15.76 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994262 | CMS |
| ABBVIE INC. | $15.73 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994264 | CMS |
| ABBVIE INC. | $17.91 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994266 | CMS |
| ABBVIE INC. | $27.73 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994268 | CMS |
| ABBVIE INC. | $16.26 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994270 | CMS |
| ABBVIE INC. | $2.97 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106994272 | CMS |
| ABIOMED | $19.99 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142220006 | CMS |
| Amgen Inc. | $13.61 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117537376 | CMS |
| Astellas Pharma US Inc | $18.61 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139497094 | CMS |
| Astellas Pharma US Inc | $15.40 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139546739 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.07 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105599947 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.97 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105471607 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.60 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105482673 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.99 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086349173 | CMS |
| Exact Sciences Corporation | $18.36 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114427561 | CMS |
| Insulet Corporation | $20.71 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116802716 | CMS |
| Lilly USA, LLC | $14.84 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135791860 | CMS |
| Lilly USA, LLC | $18.24 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135791862 | CMS |
| Novo Nordisk Inc | $18.14 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100231036 | CMS |
| Novo Nordisk Inc | $19.95 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100397242 | CMS |
| Novo Nordisk Inc | $17.83 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100462336 | CMS |
| Novo Nordisk Inc | $15.98 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100281438 | CMS |
| Paratek Pharmaceuticals, Inc. | $14.12 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113926938 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.